Company
Abpro Holdings, Inc.
Abpro Holdings is a biotechnology company developing novel antibodies using discovery and engineering platforms for immuno-oncology, ophthalmology, and infectious disease.
Abpro Holdings, Inc. is a publicly traded company. Leadership tracked by CEOInsider includes M. Fathi Karatas (CEO) and M. Fatih Karatas (CEO).
Leadership
Current
Recent developments
AI summary of recent coverageRecent coverage of Abpro Holdings has focused on significant leadership transitions and regulatory challenges facing the company. The coverage documents the appointment of an interim CEO in August 2026, the company's receipt of a delisting notice, previous departures of key executives including the CFO and chief medical officer, and the completion of a business combination in late 2024. Additionally, the company has reported earnings results during the covered period.
Summarized from the headlines in the sidebar; see each source for the full story.